MedPath Search

Found 539135 clinical trials

Sort by:

Compare PPV With and Without Silicone Oil in Managing Postoperative Endophthalmitis

Not Applicable

Completed

Conditions: Endophthalmitis Following Cataract Surgery

First Posted Date: 2025-05-25

Last Posted Date: 2025-05-25

Lead Sponsor: Benha University

Target Recruit Count: 40

Registration Number: NCT06990607

Locations: 🇪🇬
Al-Azhar University, Cairo, Egypt

SYS6002 Plus JMT101 and Enlonstobart Injection as First-Line Treatment for HNSCC

Phase 2

Not yet recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: JMT101
Drug: SYS6002
Drug: SYSA1802

First Posted Date: 2025-05-25

Last Posted Date: 2025-05-25

Lead Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

Target Recruit Count: 250

Registration Number: NCT06989671

Adaptive Neoadjuvant Therapy for Esophageal Cancer

Not Applicable

Conditions: Esophageal Carcinoma
Neoadjuvant Therapy

First Posted Date: 2025-05-25

Last Posted Date: 2025-05-25

Lead Sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center

Target Recruit Count: 43

Registration Number: NCT06990178

Locations: 🇨🇳
113 Baohe Road,Longgang District,Shenzhen,China, Shenzhen, Guangdong, China

Comparison of the Analgesic Effect of Oliceridine Versus Morphine or Sufentanil for Postoperative Analgesia in Lumbar Surgeries: a Randomized Control Trial

Not Applicable

Recruiting

Conditions: Sufentanil
Morphine
Validity
Safety
Oliceridine

Interventions: Drug: Sufentanil
Drug: Oliceridine
Drug: Morphine

First Posted Date: 2025-05-25

Last Posted Date: 2025-05-25

Lead Sponsor: Anqing Municipal Hospital

Target Recruit Count: 90

Registration Number: NCT06990893

Locations: 🇨🇳
Department of Anqing Hospital Anesthesiology, Anqing, Anhui, China

The Effect of Physical Exercise After Childbirth

Not Applicable

Not yet recruiting

Conditions: Postpartum

First Posted Date: 2025-05-25

Last Posted Date: 2025-05-25

Lead Sponsor: ümran erciyes

Target Recruit Count: 108

Registration Number: NCT06990009

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Phase 3

Recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Trastuzumab deruxtecan
Drug: Rilvegostomig
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Docetaxel

First Posted Date: 2025-05-25

Last Posted Date: 2025-05-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 600

Registration Number: NCT06989112

Locations: 🇬🇧
Research Site, Northwood, United Kingdom

Outpatient Care Pathway for Patients Treated Intra-arterially for Primary Liver Cancer

Not Applicable

Not yet recruiting

Conditions: Hepato Cellular Carcinoma (HCC)

First Posted Date: 2025-05-25

Last Posted Date: 2025-05-25

Lead Sponsor: University Hospital, Angers

Target Recruit Count: 206

Registration Number: NCT06990659

Locations: 🇫🇷
University hospital of Amiens, Amiens, France
🇫🇷
University hospital of Angers, Angers, France
🇫🇷
University hospital of Besançon, Besançon, France

and more 13 locations

Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers

Not Applicable

Not yet recruiting

Conditions: Sleep Disorder
Aging

First Posted Date: 2025-05-25

Last Posted Date: 2025-05-25

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 80

Registration Number: NCT06990256

Locations: 🇨🇳
Wuchang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1

Not yet recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab
Drug: Mezigdomide
Drug: Dexamethasone

First Posted Date: 2025-05-25

Last Posted Date: 2025-05-25

Lead Sponsor: Celgene

Target Recruit Count: 62

Registration Number: NCT06988488

Locations: 🇺🇸
Local Institution - 0001, Birmingham, Alabama, United States
🇺🇸
Local Institution - 0029, New Haven, Connecticut, United States
🇺🇸
Local Institution - 0028, Hackensack, New Jersey, United States

and more 14 locations

A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults

Phase 1

Recruiting

Conditions: Chronic Hepatitis b

Interventions: Biological: AVX70371
Other: Placebo

First Posted Date: 2025-05-25

Last Posted Date: 2025-05-25

Lead Sponsor: AstriVax Therapeutics

Target Recruit Count: 16

Registration Number: NCT06989788

Locations: 🇧🇪
University Hospital Ghent - Centrum voor Vaccinologie (CEVAC), Ghent, Belgium